PDS Biotechnology narrows Q3 loss to $7.6 million as spending falls
PDS Biotechnology posted a third-quarter 2026 loss of $7.6 million, down from $9.0 million a year earlier, with $15.2 million in cash at quarter-end.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
PDS Biotechnology's net loss for the third quarter of 2026 came to $7.6 million, or $0.11 a share, against $9.0 million, or $0.19 a share, a year earlier, according to a report carried by TradingView. Operating costs dropped to $5.9 million from $8.1 million, mainly because research and development spending fell from $4.6 million to $2.1 million. Net interest expense rose to $1.7 million from $0.9 million.
Cash and equivalents stood at $15.2 million on September 30, 2026, down from $26.7 million at the end of 2025. The company also announced an initial closing of a private placement (PIPE) of up to $22.3 million, led by Nant Capital, and said PDS0301 remains its lead program.
why it matters
The narrower loss mostly reflects lower R&D outlays rather than a change in the business, so the funding picture matters more for investors. The $22.3 million figure is an upper limit, and the size of the first closing was not specified, which makes the cash runway hard to gauge. Further clinical updates on PDS0301 will be the next thing to watch.
tags
instruments
sources
- PDS Biotechnology Corporation (PDSB) Reports $7.6M Q3 Net Loss — TradingView, 13 November 2026 at 13:00 UTC
- PDS Biotechnology Reports Q3 2026 Net Loss of $7.6 Million — TradingView, 13 November 2026 at 13:13 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗